정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1612 | Not yet recruiting | Efficacy and Safety of Favipiravir and Ribavirin Formulation for Treatment of COVID-19 | COVID-19 | Drug: Ribavirin Capsules Drug: Favipiravir |
Phase 3 | The Scientific and Technological Research Council of Turkey, Ankara City Hospital Bilkent, Istanbul Umraniye Training and Research Hospital, Koc University, Monitor CRO | OTHER | 100 | All | 18 Years | Ankara University, School of Medicine, Ankara, Cebeci, Turkey Ankara City Hospital, Ankara, Turkey Koc University Hospital, Istanbul, Turkey Umraniye Training and Research Hospital, Istanbul, Turkey |
| 1611 | Recruiting | Efficacy and Safety of Favipiravir in Covid-19 Patients in Indonesia | Covid19 | Drug: Favipiravir Drug: Azithromycin |
Phase 3 | Ina-Respond, Center for Research and Development of Health Resources and Services, National Institute of Health Research and Development (NIHRD), Indonesia | OTHER | 210 | All | 18 Years ~ 59 Years | RSJ Soerodjo, Magelang, Central Java, Indonesia RSUP Dr. Kariadi, Semarang, Central Of Java, Indonesia RSPI Sulianti Saroso, Jakarta, DKI Jakarta, Indonesia |
| 1610 | Completed | Efficacy and Safety of Favipiravir in Management of COVID-19 | Coronavirus Disease (COVID-19) | Drug: favipiravir Drug: Standard of care therapy |
Phase 3 | Ain Shams University | OTHER | 100 | All | 18 Years ~ 80 Years | Faculty of Medicine Ain Shams University Research Institute- Clinical Research Center, Cairo, Non-US, Egypt |
| 1609 | Completed | Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 Infection | COVID-19 | Drug: Danoprevir+Ritonavir | Phase 4 | Huoshenshan Hospital, Ascletis Pharmaceuticals Co., Ltd. | OTHER | 10 | All | 18 Years ~ 75 Years | Huoshenshan Hostipal, Wuhan, Hubei, China |
| 1608 | Completed | Efficacy and Safety of Guduchi Ghan Vati in the Management of Asymptomatic COVID-19 Infection | Covid19 | Drug: Guduchi Ghan Vati | Not Applicable | Aarogyam UK, Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University | OTHER | 46 | All | 18 Years | Dr. Sarvepalli Radhakrishnan Rajasthan Ayurved University, Jodhpur, Rajasthan, India |
| 1607 | Active, not recruiting | Efficacy and Safety of Heterologous and Homologous COVID-19 Vaccination | Healthy Adult Volunteers | Biological: ChAdOx1-nCov-19 (Astra-Zeneca) Biological: SARS-CoV-2 messenger RNA-1273 (Moderna) vaccine |
Not Applicable | National Taiwan University Hospital, Taoyuan General Hospital, Ministry of Health and Welfare,Taoyuan,Taiwan | OTHER | 500 | All | 20 Years ~ 65 Years | National Taiwan University Hospital, Taipei City, X, Taiwan |
| 1606 | Active, not recruiting | Efficacy and Safety of High-dose Vitamin C Combined With Chinese Medicine Against Coronavirus Pneumonia (COVID-19) | COVID-19 | Drug: Alpha-interferon alpha, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste, fumigation/inhalation of vitamin C Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and 5% glucose Drug: Alpha-interferon, abidol, ribavirin, Buzhong Yiqi plus and minus formula, Huhuang Detoxicity Paste, Baimu Qingre Jiedu Paste and high-dose vitamin C treatment |
Not Applicable | Xi'an International Medical Center Hospital | OTHER | 60 | All | 18 Years ~ 70 Years | Xi'an International Medical Center Hospital, Xi'an, Shaanxi, China |